Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
February 2, 2007

CSL Behring and Bayer Extend Agreement Related to Hemophilia

  • CSL Behring reached an agreement with Bayer HealthCare to continue the supply and distribution of a therapy for the treatment of hemophilia A. Bayer will provide Helixate® recombinant coagulation Factor VIII to CSL Behring through 2017.

    Additionally, Bayer was granted a license to intellectual property related to recombinant FVIII. At the same time, the companies settled outstanding litigation relating to the supply of recombinant Factor VIII.

  • You’re all set! Thank you for subscribing to GEN Highlights.